Humulin R Articles

ENALAPRIL - A NEW HOPE FOR DIABETICS?

24 May 1993

SCIOS NOVA HAS THREE DRUGS IN CLINICAL TRIALS

17 May 1993

AMYLIN IN GOOD POSITION

17 May 1993

NOVO NORDISK EXPANDING ITS FOCUS

26 April 1993

SYNTHELABO RESEARCH AND DEVELOPMENT

12 April 1993

UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS

5 April 1993

CELTRIX' IGF-BP3

5 April 1993

HOECHST FILES FOR HUMAN INSULIN PRODUCTION

29 March 1993

WORLD ENDOCRINE MARKET AND FORECASTS

29 March 1993

HOECHST DISSATISFIED WITH 1992 RESULTS

29 March 1993

NOVO NORDISK TAX CUTS BENEFIT

22 March 1993

PHARMACEUTICAL DESIGN: EPITOPE SELECTION

15 March 1993

FRANCE'S SERVIER COMING OUT OF SHELL?

8 March 1993

SCIOS NOVA HAS BROAD TECHNOLOGY BASE

8 March 1993

SIGNIFICANT MOVES BY PHARMA COS IN FT 500

1 March 1993

UK: NOVO INSULIN PEN INJECTOR LAUNCHED

15 February 1993

GENENTECH FRENCH PATENT REVOKED

15 February 1993

RUSSIA INSULIN DEBT: 12 MILLION AT RISK

15 February 1993

HUMAN INSULIN STUDY SUPPORTS USE

1 February 1993

NOVO NORDISK NASAL INSULIN DELAYS

25 January 1993

REGENERON ENTERS PHASE II STUDY

25 January 1993

HOECHST BUILDS US NEURO CENTER

4 January 1993

JAPANESE DIABETES DRUGS IN DEVELOPMENT

4 January 1993

PFIZER TO FILE NDA FOR DIABETES DRUG

14 December 1992

BOEH-INGELHEIM'S IMMUKIN LAUNCHED IN UK

7 December 1992

FUJISAWA'S PROMISING R&D PIPELINE

9 November 1992

ANTIHYPERTENSIVES IN DIABETICS

2 November 1992

HOECHST GERMAN GENTECH DEVT HELD BACK AGAIN

2 November 1992

NOVO NORDISK GROWTH PROSPECTS

12 October 1992

ANTI-CD3 POTENTIAL DIABETES TREATMENT

12 October 1992

US/EURO PHARMA INROADS INTO CIS

5 October 1992

Tokyo: Stock Comment

6 July 1992

INSULIN MIMIC CAN BE GIVEN ORALLY

29 June 1992

Kabi's Laron's Syndrome Treatment

29 June 1992

HORMONE REPLACEMENT THERAPY: US REPORT

8 June 1992

good year for Sankyo

1 June 1992

rIGF-1 AND LARON-TYPE DWARFISM

1 June 1992

DELAYS TO INDIA'S NEW DRUG POLICY

1 June 1992

1st QTR PROFITS JUMP AT NOVO NORDISK

18 May 1992

DIABETES TREATMENT IN TANZANIA

18 May 1992

Novel Diabetes treatment

18 May 1992

GENENTECH'S EXPANDING PRODUCT PORTFOLIO

11 May 1992

REVENUES DECLINE, R&D UP AT SCIOS IN 1991

4 May 1992

PROJECT REVIEW FROM NOVO NORDISK

27 April 1992

WARNER-LAMBERT'S VIEW TO THE FUTURE

27 April 1992

NOVO NORDISK TO INVEST IN SPAIN

20 April 1992

NOVO-NORDISK'S rec INSULIN LAUNCHED IN FRANCE

13 April 1992

UPJOHN UPDATES ON R&D PROGRESS

13 April 1992

NOVO-NORDISK'S rec INSULIN LAUNCHED IN FRANCE

13 April 1992

WORLD MARKET FOR BIO-DRUGS

6 April 1992

WORLD MARKET FOR BIO-DRUGS

6 April 1992

HOECHST ON DRUG DEV'T ECONOMIC PRESSURES

23 March 1992

TEN YEARS OF ACE INHIBITION

23 March 1992

NOVO REPORTS 28% PRETAX PROFIT JUMP

16 March 1992

CAL BIO FOURTH QUARTER LOSS

9 March 1992

MORTALITY BENEFIT WITH GYNEX' OXANDRIN

17 February 1992

BUSH SEEKS $797 MILL FOR FDA IN 1993

10 February 1992

ADVANCE IN DIABETES RESEARCH

3 February 1992

POLAND DRUG IMPORT POLICY MOVES

3 February 1992

SHIONOGI LAUNCHES HUMULIN U IN JAPAN

3 February 1992

DIABETES TREATMENT HOPE

3 February 1992

GUT HORMONE COULD DISPLACE INSULIN

27 January 1992

AMYLIN SHARES SURGE

27 January 1992

GENENTECH TO START TRIALS OF HER-2

27 January 1992

AGGRESSIVE MARKETING BOOSTS YAMANOUCHI

20 January 1992

HOECHST RESEARCH: A "TRI-REGIONAL" FOCUS

20 January 1992

SANDOSTATIN IN DIABETES

20 January 1992

ARTIFICIAL PANCREAS

20 January 1992

LILLY INVESTING IN FRANCE

13 January 1992

CELTRIX TO BECOME MAJOR BIOTECH PLAYER

13 January 1992

ELI LILY EXPANDS IN FRANCE

6 January 1992

Novo Nordisk ups 2008 guidance